Page last updated: 2024-09-04

vatalanib and Stomach Neoplasms

vatalanib has been researched along with Stomach Neoplasms in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	1 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Cejka, D; Fuereder, T; Hoeflmayer, D; Jaeger-Lansky, A; Koehrer, S; Preusser, M; Wacheck, V; Ying, L	1

Other Studies

1 other study(ies) available for vatalanib and Stomach Neoplasms

Article	Year
Effects of vatalanib on tumor growth can be potentiated by mTOR blockade in vivo. Cancer biology & therapy, 2010, Jun-01, Volume: 9, Issue:11 Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Line, Tumor; Cell Proliferation; Drug Synergism; Enzyme-Linked Immunosorbent Assay; Everolimus; Humans; Immunosuppressive Agents; Mice; Mice, Nude; Neovascularization, Pathologic; Phthalazines; Protein Kinase Inhibitors; Pyridines; Receptors, Vascular Endothelial Growth Factor; Signal Transduction; Sirolimus; Stomach Neoplasms; TOR Serine-Threonine Kinases; Tumor Burden; Vascular Endothelial Growth Factor A; Xenograft Model Antitumor Assays	2010

Article

Year

Effects of vatalanib on tumor growth can be potentiated by mTOR blockade in vivo.

Cancer biology & therapy, 2010, Jun-01, Volume: 9, Issue:11

Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Line, Tumor; Cell Proliferation; Drug Synergism; Enzyme-Linked Immunosorbent Assay; Everolimus; Humans; Immunosuppressive Agents; Mice; Mice, Nude; Neovascularization, Pathologic; Phthalazines; Protein Kinase Inhibitors; Pyridines; Receptors, Vascular Endothelial Growth Factor; Signal Transduction; Sirolimus; Stomach Neoplasms; TOR Serine-Threonine Kinases; Tumor Burden; Vascular Endothelial Growth Factor A; Xenograft Model Antitumor Assays

2010